1-20 of 651 results for subject:Benzodiazepines
Librarians' tools
- Search time
- 0.553 seconds
- Solr query time
- 0.005 seconds
- Search query
- subject:Benzodiazepines
- We searched for
- subject_t:Benzodiazepines OR subject_ses:290331
Type
House
Session
More
Year
More
Department
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, how many prescriptions were issued for each drug categorised under the (a) (i) clonazepam and (ii) other benzodiazepines, (b) z-drugs, (c) antidepressants, (d) opioids, (e) pregabalin and (f) gabapentin drug groups in the last 12 months and the total...
To ask the Secretary of State for Health and Social Care, how many prescriptions were issued for each drug categorised under the (a) (i) clonazepam and (ii) other benzodiazepines, (b) z-drugs, (c) antidepressants, (d) opioids, (e) pregabalin and (f) gabapentin drug groups in the last 12 months and the total...
The NHSBSA holds patient identifiable information for the number of items dispensed and claimed for reimbursement. The following table shows the total number of prescription items for clonazepam and other benzodiazepines, z-drugs, antidepressants, opioids, pregabalin, and gabapentin drug groups, as well as the percentage and number of unique identified patients for those drug groups for 2024/25:
Drug Group | Total number of prescription items | Total number of unique identified patients | Percentage of items where the patient has been identified |
Clonazepam | 1,073,708 | 84,379 | 98.19% |
Other benzodiazepines | 6,560,170 | 1,122,860 | 97.01% |
Clonazepam and other benzodiazepines | 7,633,878 | 1,193,477 | 97.17% |
Z-drugs | 4,888,101 | 721,641 | 98.20% |
Antidepressants | 92,642,110 | 8,888,229 | 99.25 |
Opioids | 39,015,440 | 5,559,691 | 98.99 |
Pregabalin | 9,607,609 | 851,696 | 99.44** |
Gabapentin | 7,413,842 | 783,591 | 99.44** |
Notes:
- for the clonazepam and other benzodiazepines drug groups, the figures represent patients who have received any combination of clonazepam and/or other benzodiazepines, as no patient is counted twice within this row, even where multiple medications have been received; and
- for the pregabalin, and gabapentin drug groups, please note these figures refer to the combined category of gabapentinoids.
Patient count totals included in the table should not be aggregated.
To ask the Secretary of State for Health and Social Care, how many prescriptions were issued for each drug categorised under the (a) (i) clonazepam and (ii) other benzodiazepines, (b) z-drugs, (c) antidepressants, (d) opioids, (e) pregabalin and (f) gabapentin drug groups in the (i) last 12 months and (ii)...
To ask the Secretary of State for Health and Social Care, how many prescriptions were issued for each drug categorised under the (a) (i) clonazepam and (ii) other benzodiazepines, (b) z-drugs, (c) antidepressants, (d) opioids, (e) pregabalin and (f) gabapentin drug groups in the (i) last 12 months and (ii)...
The following table shows the number of items dispensed and claimed for reimbursement for each of the categories requested, covering the most recently published 12-month period and the 12 months prior:
Drug group | Financial year | Total number of items |
Clonazepam | 2022/23 | 1,048,081 |
2023/24 | 1,059,421 | |
Other benzodiazepines | 2022/23 | 7,156,845 |
2023/24 | 6,814,129 | |
Clonazepam and other benzodiazepines | 2022/23 | 8,204,926 |
2023/24 | 7,873,550 | |
Z-drugs | 2022/23 | 5,316,627 |
2023/24 | 5,113,574 | |
Antidepressants | 2022/23 | 86,263,722 |
2023/24 | 89,131,582 | |
Opioids | 2022/23 | 39,401,517 |
2023/24 | 39,046,206 | |
Pregabalin | 2022/23 | 8,775,699 |
2023/24 | 9,180,793 | |
Gabapentin | 2022/23 | 7,413,759 |
2023/24 | 7,408,375 |
Source: NHS Business Services Authority.
In addition, the following table shows the patient identifiable information for the number of items dispensed and claimed for reimbursement for each of the categories requested, for the most recently published 12-month period and the 12 months prior:
Drug group | Financial Year | Total number of unique identified patients | Percentage of items where the patient has been identified |
Clonazepam | 2022/23 | 85,613 | 98.22% |
2023/24 | 85,191 | 98.16% | |
Other benzodiazepines | 2022/23 | 1,253,962 | 97.06% |
2023/24 | 1,186,001 | 97.01% | |
Clonazepam and other benzodiazepines | 2022/23 | 1,324,792 | 97.21% |
2023/24 | 1,256,941 | 97.17% | |
Z-drugs | 2022/23 | 795,959 |
|
2023/24 | 764,743 |
| |
Antidepressants | 2022/23 | 8,563,148 |
|
2023/24 | 8,747,095 |
| |
Opioids | 2022/23 | 5,593,035 |
|
2023/24 | 5,562,718 |
| |
Pregabalin | 2022/23 | 786,403 |
|
2023/24 | 823,231 |
| |
Gabapentin | 2022/23 | 808,562 |
|
2023/24 | 799,144 |
|
Source: NHS Business Services Authority.
Notes:
- for clonazepam and other benzodiazepines, this is the number of unique patients who have received any combination of clonazepam and/or other benzodiazepines, and no patient is counted twice even where multiple medications have been received;
- the figures for pregabalin and gabapentin refer to the combined category of gabapentinoids; and
- the data in this answer in both tables on opioids, is not directly comparable to data from the previous Parliamentary Questions, PQ137238 and PQ137239, referenced in the question, as these tables refer to opioids in general, while the previous Parliamentary Questions referred to opioid analgesics only.
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 27 January 2021 to Question 137239 on Prescription Drugs, what information his Department holds on the number of patients who have been prescribed drugs categorised under the (a) (i) clonazepam and (ii) other...
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 27 January 2021 to Question 137239 on Prescription Drugs, what information his Department holds on the number of patients who have been prescribed drugs categorised under the (a) (i) clonazepam and (ii) other...
The following table shows the number of items dispensed and claimed for reimbursement for each of the categories requested, covering the most recently published 12-month period and the 12 months prior:
Drug group | Financial year | Total number of items |
Clonazepam | 2022/23 | 1,048,081 |
2023/24 | 1,059,421 | |
Other benzodiazepines | 2022/23 | 7,156,845 |
2023/24 | 6,814,129 | |
Clonazepam and other benzodiazepines | 2022/23 | 8,204,926 |
2023/24 | 7,873,550 | |
Z-drugs | 2022/23 | 5,316,627 |
2023/24 | 5,113,574 | |
Antidepressants | 2022/23 | 86,263,722 |
2023/24 | 89,131,582 | |
Opioids | 2022/23 | 39,401,517 |
2023/24 | 39,046,206 | |
Pregabalin | 2022/23 | 8,775,699 |
2023/24 | 9,180,793 | |
Gabapentin | 2022/23 | 7,413,759 |
2023/24 | 7,408,375 |
Source: NHS Business Services Authority.
In addition, the following table shows the patient identifiable information for the number of items dispensed and claimed for reimbursement for each of the categories requested, for the most recently published 12-month period and the 12 months prior:
Drug group | Financial Year | Total number of unique identified patients | Percentage of items where the patient has been identified |
Clonazepam | 2022/23 | 85,613 | 98.22% |
2023/24 | 85,191 | 98.16% | |
Other benzodiazepines | 2022/23 | 1,253,962 | 97.06% |
2023/24 | 1,186,001 | 97.01% | |
Clonazepam and other benzodiazepines | 2022/23 | 1,324,792 | 97.21% |
2023/24 | 1,256,941 | 97.17% | |
Z-drugs | 2022/23 | 795,959 |
|
2023/24 | 764,743 |
| |
Antidepressants | 2022/23 | 8,563,148 |
|
2023/24 | 8,747,095 |
| |
Opioids | 2022/23 | 5,593,035 |
|
2023/24 | 5,562,718 |
| |
Pregabalin | 2022/23 | 786,403 |
|
2023/24 | 823,231 |
| |
Gabapentin | 2022/23 | 808,562 |
|
2023/24 | 799,144 |
|
Source: NHS Business Services Authority.
Notes:
- for clonazepam and other benzodiazepines, this is the number of unique patients who have received any combination of clonazepam and/or other benzodiazepines, and no patient is counted twice even where multiple medications have been received;
- the figures for pregabalin and gabapentin refer to the combined category of gabapentinoids; and
- the data in this answer in both tables on opioids, is not directly comparable to data from the previous Parliamentary Questions, PQ137238 and PQ137239, referenced in the question, as these tables refer to opioids in general, while the previous Parliamentary Questions referred to opioid analgesics only.
My Lords, this order was laid before Parliament on 2 September. I thank the Advisory Council on the Misuse of Drugs, which I shall, for the purposes of brevity, call the ACMD from here on in, for its detailed and thorough advice, which has informed this draft order.
The purpose of...
My Lords, this order was laid before Parliament on 2 September. I thank the Advisory Council on the Misuse of Drugs, which I shall, for the purposes of brevity, call the ACMD from here on in, for its detailed and thorough advice, which has informed this draft order.
The purpose of...
My Lords, we accept the recommendation of the advisory council and support the tightening of these regulations. I shall add a couple of comments. In relation to synthetic opioids, given the continual emergence of new individual nitazenes, we are in favour of introducing a generic control for these substances. They...
My Lords, we accept the recommendation of the advisory council and support the tightening of these regulations. I shall add a couple of comments. In relation to synthetic opioids, given the continual emergence of new individual nitazenes, we are in favour of introducing a generic control for these substances. They...
My Lords, the Conservative Party welcomes this order. It controls six substances, introduces a generic definition for nitazenes as class A drugs and controls 16 substances as class C drugs. These Benches believe deeply in the principles of law and order, personal responsibility and the protection of our communities. This...
My Lords, the Conservative Party welcomes this order. It controls six substances, introduces a generic definition for nitazenes as class A drugs and controls 16 substances as class C drugs. These Benches believe deeply in the principles of law and order, personal responsibility and the protection of our communities. This...
I am grateful to the noble Baroness, Lady Doocey, and the noble Lord, Lord Sharpe, for their contributions from both Opposition Front Benches.
I will deal initially with the noble Baroness, Lady Doocey. She made an important point about consultation and the further discussions around a potential generic definition for the...
I am grateful to the noble Baroness, Lady Doocey, and the noble Lord, Lord Sharpe, for their contributions from both Opposition Front Benches.
I will deal initially with the noble Baroness, Lady Doocey. She made an important point about consultation and the further discussions around a potential generic definition for the...
Lords motion to consider. Agreed to on question.
Lords motion to consider. Agreed to on question.
Motion to consider. Agreed to on question.
Motion to consider. Agreed to on question.
Lords motion to consider. Agreed to on question.
Lords motion to consider. Agreed to on question.
My Lords, this draft order, which was laid before Parliament on 27 November last year, proposes amendments to the Misuse of Drugs Act 1971 to control 15 substances as class A drugs, four substances as class B drugs and one substance as a class C drug. To achieve this, it...
My Lords, this draft order, which was laid before Parliament on 27 November last year, proposes amendments to the Misuse of Drugs Act 1971 to control 15 substances as class A drugs, four substances as class B drugs and one substance as a class C drug. To achieve this, it...
My Lords, in speaking for these Benches I would ordinarily speak from a health perspective. From our point of view, a lot of the drug abuse issues fall within that category. We are obviously dealing with a Home Office statutory instrument today, but I hope that the Minister will indulge...
My Lords, in speaking for these Benches I would ordinarily speak from a health perspective. From our point of view, a lot of the drug abuse issues fall within that category. We are obviously dealing with a Home Office statutory instrument today, but I hope that the Minister will indulge...
My Lords, we too welcome the amendments in this instrument. I will start with two specific questions and then make some more general comments.
First, beyond adding the specific substances which the Minister referred to in his speech and in the document, what more are the Government doing to address the...
My Lords, we too welcome the amendments in this instrument. I will start with two specific questions and then make some more general comments.
First, beyond adding the specific substances which the Minister referred to in his speech and in the document, what more are the Government doing to address the...
My Lords, I thank both noble Lords for their contributions to this short debate. I take on board the personal experience of the noble Lord, Lord Ponsonby, in the States; his observations are obviously extremely interesting. Perhaps it is worth pointing out that just under half of all drug poisoning...
My Lords, I thank both noble Lords for their contributions to this short debate. I take on board the personal experience of the noble Lord, Lord Ponsonby, in the States; his observations are obviously extremely interesting. Perhaps it is worth pointing out that just under half of all drug poisoning...
I specifically asked about the Glasgow drug consumption rooms and whether there is a UK oversight of the way they are operating, rather than just a Scottish Government oversight.
I specifically asked about the Glasgow drug consumption rooms and whether there is a UK oversight of the way they are operating, rather than just a Scottish Government oversight.
With apologies, I forgot that question and, as it happens, I also do not know the answer—so I will have to find out and write to the noble Lord.
With apologies, I forgot that question and, as it happens, I also do not know the answer—so I will have to find out and write to the noble Lord.
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 27 January 2021 to Question 137239 on Prescription Drugs, what information his Department holds on the number of unique patients who have been prescribed drugs categorised under the drug groups (a) benzodiazepines including...
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 27 January 2021 to Question 137239 on Prescription Drugs, what information his Department holds on the number of unique patients who have been prescribed drugs categorised under the drug groups (a) benzodiazepines including...
The methodologies used by the NHS Business Services Authority (NHSBSA) for calculating these statistics have changed since January 2021. Therefore, the below tables include data for each of the last five financial years to address the additional two-year datasets requested as well as reflect the new methodologies used.
The following table shows the number of unique patients who were prescribed benzodiazepines including clonazepam in each financial year 2018/2019 to 2022/2023:
Financial Year | Total number of unique identified patients - benzodiazepines including clonazepam | Percentage (%) of items where the patient has been identified |
2018/2019 | 1,545,014 | 95.27 |
2019/2020 | 1,497,077 | 95.97 |
2020/2021 | 1,368,092 | 97.16 |
2021/2022 | 1,339,417 | 97.23 |
2022/2023 | 1,324,792 | 97.21 |
The following table shows the number of unique patients who were prescribed Z-Drugs in each financial year from 2018/2019 to 2021/2022:
Financial Year | Total number of unique identified patients – Z-Drugs | Percentage (%) of items where the patient has been identified |
2018/2019 | 945,510 | 96.65 |
2019/2020 | 897,451 | 96.94 |
2020/2021 | 876,746 | 98.05 |
2021/2022 | 825,382 | 98.12 |
The following table shows the number of unique patients who were prescribed an antidepressant in each financial year from 2018/2019 to 2022/2023:
Financial Year | Total number of unique identified patients – Antidepressants | Percentage (%) of items where the patient has been identified |
2018/2019 | 7,590,802 | 97.92 |
2019/2020 | 7,856,297 | 98.21 |
2020/2021 | 7,909,516 | 99.10 |
2021/2022 | 8,359,838 | 99.14 |
2022/2023 | 8,563,148 | 99.16 |
The following table shows the number of unique patients who were prescribed opioids from financial year 2018/2019 to 2021/2022:
Financial Year | Total number of unique identified patients - Opioids (includes compound analgesics) | Percentage (%) of items where the patient has been identified | Total number of unique identified patients - Opioid Analgesics (excludes compound analgesics) |
2018/2019 | 5,935,454 | 96.65 | 3,036,777 |
2019/2020 | 5,730,095 | 96.94 | 2,971,092 |
2020/2021 | 5,525,899 | 98.05 | 2,883,897 |
2021/2022 | 5,589,348 | 98.12 | 2,927,983 |
Note: Our reply to the previous question predated the official statistics used here, and used a different classification of opioids using the standard classification used in the NHSBSA Data Warehouse. Comparable data is shown in the final column of the above table; this counts patients without including any prescriptions for compound analgesics such as co-codamol and co-dydramol.
All figures included above are correct as of 5 September 2023 and could be subject to revision once audited reports are published.
To ask His Majesty's Government whether they intend to conduct a review of efficacy, safety and risk of addiction relating to the long-term use of benzodiazepines.
To ask His Majesty's Government whether they intend to conduct a review of efficacy, safety and risk of addiction relating to the long-term use of benzodiazepines.
The safety of medicines on the United Kingdom market are continuously monitored by the Medicines and Healthcare products Regulatory Agency (MHRA). There are currently no plans to conduct any further reviews into the harms associated with benzodiazepines, Z-drugs and antidepressants, however, any new data would be carefully considered. Details about the possible risks and side effects are outlined in the product information available for each medicine.
Benzodiazepines and Z-drugs are authorised for short term use, two to four weeks, and should not be used long term due to the risk of dependence and subsequent withdrawal reactions. Healthcare professionals have been reminded of these risks by the MHRA, the Department and professional bodies which have highlighted the extensive warnings about the risks of dependence, the need to limit prescribing and advice about gradual withdrawal.
To ask His Majesty's Government what assessment they have made of long-term and permanent harm caused by the use of benzodiazepines, Z-drugs and antidepressants.
To ask His Majesty's Government what assessment they have made of long-term and permanent harm caused by the use of benzodiazepines, Z-drugs and antidepressants.
The safety of medicines on the United Kingdom market are continuously monitored by the Medicines and Healthcare products Regulatory Agency (MHRA). There are currently no plans to conduct any further reviews into the harms associated with benzodiazepines, Z-drugs and antidepressants, however, any new data would be carefully considered. Details about the possible risks and side effects are outlined in the product information available for each medicine.
Benzodiazepines and Z-drugs are authorised for short term use, two to four weeks, and should not be used long term due to the risk of dependence and subsequent withdrawal reactions. Healthcare professionals have been reminded of these risks by the MHRA, the Department and professional bodies which have highlighted the extensive warnings about the risks of dependence, the need to limit prescribing and advice about gradual withdrawal.